Novo Nordisk Pharmatech A Slash S
Novo Nordisk Pharmatech A/S, headquartered in Denmark (DK), is a leading player in the pharmaceutical and biotechnology industry, specialising in the production of high-quality ingredients for the global healthcare market. Founded as a subsidiary of Novo Nordisk in 2000, the company has established itself as a trusted provider of excipients and active pharmaceutical ingredients (APIs), particularly for insulin and biopharmaceutical applications. With a strong focus on innovation and sustainability, Novo Nordisk Pharmatech offers unique products such as insulin stabilisers and high-purity excipients, which are essential for the formulation of effective medications. The company’s commitment to quality and regulatory compliance has positioned it as a preferred partner for pharmaceutical manufacturers worldwide. Notable achievements include its robust supply chain and dedication to environmental responsibility, reinforcing its status as a key contributor to the healthcare sector.
DitchCarbon Score
How does Novo Nordisk Pharmatech A Slash S's carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Health Services industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Novo Nordisk Pharmatech A Slash S's score of 8 is lower than 99% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Novo Nordisk Pharmatech A Slash S's reported carbon emissions
In 2023, Novo Nordisk Pharmatech A/S reported total carbon emissions of approximately 3,573,000 kg CO2e. This figure includes 51,000 kg CO2e from Scope 1 emissions and a significant 3,522,000 kg CO2e from Scope 3 emissions, which encompasses areas such as business travel, accounting for 79,000 kg CO2e. The company's emissions have fluctuated over recent years. In 2022, total emissions were about 1,830,000 kg CO2e, with Scope 1 emissions at 47,000 kg CO2e and Scope 3 emissions at 1,828,000 kg CO2e. In 2021, total emissions were approximately 1,445,000 kg CO2e, with Scope 1 at 50,000 kg CO2e and Scope 3 at 1,395,000 kg CO2e. The year 2020 saw a total of about 170,000 kg CO2e, with Scope 1 emissions of 61,000 kg CO2e and Scope 3 emissions at 1,921,000 kg CO2e. In 2019, emissions peaked at approximately 2,109,000 kg CO2e, with Scope 1 at 47,000 kg CO2e and Scope 3 at 2,062,000 kg CO2e. The earliest data from 2018 indicated total emissions of about 278,000 kg CO2e. Despite these figures, Novo Nordisk Pharmatech A/S has not publicly disclosed specific reduction targets or initiatives aimed at decreasing their carbon footprint. The absence of defined climate pledges or science-based targets suggests that while the company is aware of its emissions, it may not yet have formalised a comprehensive strategy for significant reductions.
Unlock detailed emissions data
Access structured emissions data, company-specific emission factors, and source documents
Add to project| 2019 | 2020 | 2021 | 2022 | 2023 | |
|---|---|---|---|---|---|
| Scope 1 | 47,000 | 00,000 | 00,000 | 00,000 | 00,000 |
| Scope 2 | - | - | - | - | - |
| Scope 3 | 2,062,000 | 0,000,000 | 0,000,000 | 0,000,000 | 0,000,000 |
Industry emissions intensity
Location emissions intensity
Reduction initiatives & disclosure networks
Companies disclose and commit to reducing emissions to show they are serious about reducing emissions impact over time. They can also help a company track its progress over time.
Novo Nordisk Pharmatech A Slash S is not committed to any reduction initiatives we track. This may change over time as the company engages with new initiatives or updates its commitments. DitchCarbon will update this information as it becomes available.
